603127 昭衍新药
2026/03 - 三个月2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)2.8243.6310.9064.82314.024
总资产报酬率 ROA (%)2.4183.1220.7633.89411.367
投入资产回报率 ROIC (%)2.4973.2360.7904.08911.932

边际利润分析
销售毛利率 (%)20.48620.71128.42842.61747.898
营业利润率 (%)80.95320.3905.17021.33854.041
息税前利润/营业总收入 (%)76.94216.3300.21114.97447.854
净利润/营业总收入 (%)75.39517.9683.45616.47647.320

收益指标分析
经营活动净收益/利润总额(%)-7.067-1.656244.702148.82668.484
价值变动净收益/利润总额(%)112.318137.951-87.503-46.55629.241
营业外收支净额/利润总额(%)0.053-0.148-0.296-0.0291.158

偿债能力分析
流动比率 (X)4.0174.5344.5304.8543.215
速动比率 (X)2.7783.3173.1993.5842.025
资产负债率 (%)14.74314.01114.01617.41420.970
带息债务/全部投入资本 (%)10.1848.5998.79211.43512.762
股东权益/带息债务 (%)859.9861,038.4521,011.605749.269657.404
股东权益/负债合计 (%)578.260613.684613.442474.155376.548
利息保障倍数 (X)-18.979-4.052-0.043-2.355-7.016

营运能力分析
应收账款周转天数 (天)51.91839.34134.53030.71024.369
存货周转天数 (天)532.623395.906416.385535.589441.019